Dyadic Secures Ebola Preparedness Partnerships as C1 Platform Delivers Proteins in 15 Days
DYAI•Dyadic’s C1 platform delivers purified recombinant antigen or monoclonal antibody in approximately 15 days and has secured Ebola preparedness collaborations with Scripps Research, CEPI and the European Vaccines Hub. The company launched recombinant human albumin, DNase I and bovine chymosin to expand commercial adoption across life sciences and industrial markets.
1. Ebola Preparedness Collaborations
Dyadic’s C1 platform has secured collaborations with Scripps Research, CEPI and the European Vaccines Hub to accelerate Ebola antigen and monoclonal antibody development amid the Bundibugyo outbreak, reflecting urgent demand for rapid-response biologics manufacturing.
2. Platform Capabilities and Speed
The proprietary C1 microbial protein production system can transition from a codon-optimized viral gene sequence to purified recombinant antigen or antibody in approximately 15 days, leveraging high expression levels, flexible microbial bioreactors and reduced timelines.
3. Commercial Adoption and Product Launches
Beyond infectious disease applications, Dyadic recently launched recombinant human albumin via Proliant, DNase I through Fermbox Bio, and bovine chymosin with Inzymes, while advancing recombinant transferrin and growth factor products across life sciences, food, nutrition and industrial markets.
